NCT04643132

Brief Summary

Purpose: To explore effects of S-ketamine on postoperative pain and cognitive dysfunction after tibial fracture and orthopedic surgery. To evaluate and examine the incidence of adverse effects with the purpose of selecting the optimum dose.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P75+ for not_applicable postoperative-pain

Timeline
Completed

Started Dec 2020

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 17, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 24, 2020

Completed
21 days until next milestone

Study Start

First participant enrolled

December 15, 2020

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 15, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 15, 2021

Completed
Last Updated

August 13, 2021

Status Verified

August 1, 2021

Enrollment Period

11 months

First QC Date

November 17, 2020

Last Update Submit

August 7, 2021

Conditions

Keywords

S-ketaminetibial fractureorthopedic surgerypain intensity

Outcome Measures

Primary Outcomes (1)

  • Mechanical hyperalgesia threshold on the palms of feet

    The mechanical hyperalgesia threshold was defined as the lowest force (g) necessary to bend a Von Frey filament, which was perceived to be painful by the patient and measured by Von Frey filament.

    48 hours after surgery

Secondary Outcomes (7)

  • Pain Score (NRS)

    48 hours after surgery

  • Mechanical Hyperalgesia Threshold on the Dominant Inner Forearm

    48 hours after surgery

  • Time of First Postoperative Analgesic Requirement

    1 hour after surgery

  • Total Dose of First Postoperative Analgesic Requirement

    1 hour after surgery

  • Cumulative Sufentanyl Consumption

    48 hours after surgery

  • +2 more secondary outcomes

Study Arms (3)

Normal saline in patients

PLACEBO COMPARATOR

After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20 ml/h normal saline until starting skin suture.

Drug: Normal saline

S-ketamine at low dose in patients

ACTIVE COMPARATOR

After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.

Drug: S-ketamine (low-dose)

S-ketamine at high dose in patients

ACTIVE COMPARATOR

After the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.

Drug: S-ketamine (high-dose)

Interventions

After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.

Also known as: 0. 9% Sodium Chloride Injection
Normal saline in patients

After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.

Also known as: Esketamine Hydrochloride Injection
S-ketamine at low dose in patients

After the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.

Also known as: Esketamine Hydrochloride Injection
S-ketamine at high dose in patients

Eligibility Criteria

Age65 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • Subject is scheduled to undergo tibial fracture with orthopedic surgery under a short general anesthesia of less than 2 hours
  • Subject's American Society of Anesthesiologists physical status is I-II.
  • The subject's parent/legally authorized guardian has given written informed consent to participate.

You may not qualify if:

  • Subject has a diagnosis of bronchial asthma, coronary heart disease, severe hypertension, renal failure or liver failure.
  • Subject has a diagnosis of Insulin dependent diabetes.
  • Subject is allergy and contraindication to S-ketamine.
  • Subject has a history of chronic pain, a history of alcohol or opioid abuse, pre- existing therapy with opioids.
  • Subject has any contraindication for the use of patient-controlled analgesia (PCA).
  • Subject is pregnant or breast-feeding.
  • Subject is obese (body mass index \>30kg/m\^2).
  • Subject is incapacity to comprehend pain assessment and cognitive assessment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tianjin Medical University General Hospital

Tianjin, 300052, China

RECRUITING

Related Publications (2)

  • Zhang L, Terrando N, Xu ZZ, Bang S, Jordt SE, Maixner W, Serhan CN, Ji RR. Distinct Analgesic Actions of DHA and DHA-Derived Specialized Pro-Resolving Mediators on Post-operative Pain After Bone Fracture in Mice. Front Pharmacol. 2018 May 1;9:412. doi: 10.3389/fphar.2018.00412. eCollection 2018.

    PMID: 29765320BACKGROUND
  • Cui W, Li Y, Wang Z, Song C, Yu Y, Wang G, Li J, Wang C, Zhang L. Spinal caspase-6 regulates AMPA receptor trafficking and dendritic spine plasticity through netrin-1 in postoperative pain after orthopedic surgery for tibial fracture in mice. Pain. 2021 Jan;162(1):124-134. doi: 10.1097/j.pain.0000000000002021.

    PMID: 32701657BACKGROUND

MeSH Terms

Conditions

Pain, PostoperativePostoperative Cognitive ComplicationsTibial FracturesPain

Interventions

Saline SolutionSodium ChlorideEsketamine

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsNeurologic ManifestationsSigns and SymptomsCognitive DysfunctionCognition DisordersNeurocognitive DisordersMental DisordersFractures, BoneWounds and InjuriesLeg Injuries

Intervention Hierarchy (Ancestors)

Crystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical PreparationsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Guolin Wang, MD

    Tianjin Medical University General Hospital

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

November 17, 2020

First Posted

November 24, 2020

Study Start

December 15, 2020

Primary Completion

November 15, 2021

Study Completion

December 15, 2021

Last Updated

August 13, 2021

Record last verified: 2021-08

Data Sharing

IPD Sharing
Will not share

Locations